 |
May 3, 2012
Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/03/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter ended March 31, 2012. Revenue for the first quarter ended March 31, 2012 was $0.3 million. The operating loss for the first quarter ended March 31, 2012 was $7.1 million. The net loss for ...
|
|
Apr 25, 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Robert Simon as Senior Vice President of Regulatory Affairs. Mr. Simon will oversee Threshold's regulatory activities related to the development of TH-302, a clinical stage hypoxia-targeted cancer therapeutic...
|
|
Apr 13, 2012
Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the 19th Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 20, at 10:30 a.m. Eastern time in New York Ci...
|
|
Apr 11, 2012
Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck KGaA for Positive Results From Phase 2 Trial of TH-302 in Pancreatic Cancer |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/11/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany, for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("40...
|
|
Mar 30, 2012
Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Primary progression-free survival efficacy endpoint met (p=0.005)
Response rate of 27% and median PFS of 6.0 months in highest TH-302 dose group
Dose-dependent TH-302-related toxicity did not increase discontinuations du...
|
|
Mar 30, 2012
Threshold Pharmaceuticals Receives US Orphan Drug Designation for TH-302 for the Treatment of Soft Tissue Sarcoma |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.
"Following our announcement on March 16 regarding the r...
|
|
Mar 28, 2012
Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at the 2012 AACR Annual Meeting |
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/28/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that TH-302 will be featured in four presentations, including a late-breaking clinical trial session, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on March 31 - April 4, 2012, in Chicago, IL...
|
|
Mar 16, 2012
Threshold Pharmaceuticals' TH-302 Receives Orphan Drug Designation in the European Union for the Treatment of Soft Tissue Sarcoma |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/16/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.
"Receiving orphan designation for TH-302 in soft tissue sarcoma in the E...
|
|
Mar 14, 2012
Threshold Pharmaceuticals Doses First Patient in Clinical Trial Evaluating TH-302 in Multiple Myeloma |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/14/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the first patient has been dosed in its Phase 1/2 clinical trial of TH-302 as monotherapy and in combination with bortezomib in patients with relapsed/refractory multiple myeloma who have received at least two prior lines...
|
|
Mar 12, 2012
Threshold Pharmaceuticals' TH-302 to Be Featured at Symposium on Hypoxia in Cancer Hosted by the New York Academy of Sciences |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/12/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry experts at a symposium entitled Therapeutic and Diagnostic Modalities Targeting Hypoxia in Cancer, hosted by the New York Academy of Sciences on Wedne...
|
|
Mar 8, 2012
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/08/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter and year ended December 31, 2011 was $5.3 million and $25.7 million, respectively. As of December 31, 2011, Thresho...
|
|
Mar 6, 2012
Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical Study at the 2012 AACR Annual Meeting |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/06/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held on March 31st - April 4th 2012, in Chicago, IL. The presentation will ...
|
|
Feb 24, 2012
Threshold Pharmaceuticals to Present at the Cowen Health Care Conference |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/24/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Tuesday, March 6, 2012 at 10:00AM EST.
A live webcast of the prese...
|
|
Feb 21, 2012
Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/21/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005).
The combination therapy was well tolerated with a safety profile consistent with prior studies.
Threshold Pharmaceu...
|
|
Feb 17, 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/17/12 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Tillman Pearce, M.D. as its Chief Medical Officer. In this position, Dr. Pearce will oversee the development of Threshold's TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evalua...
|
|
Feb 3, 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302 |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/03/12 --
Threshold Pharmaceuticals, Inc (NASDAQ: THLD)
Threshold to receive $25 million upfront, plus further potential milestones and royalties
Deal provides Threshold option to co-commercialize in the United States
Phase 3 trial in soft tissue sarcoma on-going and randomi...
|
|
Dec 14, 2011
Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 12/14/11 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted at MD Anderson's Cancer Center in Houston, Texas.
Thirty-two patients with either acute myelogenous leukemia (A...
|
|
Dec 13, 2011
Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 12/13/11 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present an update at the Oppenheimer 22nd Annual Healthcare Conference in New York City on the Company's corporate and clinical development. This will ...
|
|
Nov 29, 2011
Threshold Pharmaceuticals to Present at the Oppenheimer Healthcare Conference |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/29/11 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the 2011 Oppenheimer 22nd Annual Healthcare Conference in New York City on Tuesday, December 13, 2011 at 9:55AM EST.
A live ...
|
|
Nov 3, 2011
Threshold Pharmaceuticals Reports Third Quarter 2011 Financial and Operational Results |
| |
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/03/11 --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter ended September 30, 2011. The net loss for the third quarter and nine months ended September 30, 2011 was $4.1 million and $20.4 million, respectively. As of September 30, 2011, Threshold...
|
|
|
